See the DrugPatentWatch profile for semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, used in the treatment of type 2 diabetes and obesity. It is currently available under the brand names Ozempic and Rybelsus, and is marketed by Novo Nordisk. The expected patent expiry date for semaglutide is a subject of interest for those in the pharmaceutical industry and patients alike.

According to DrugPatentWatch.com, the key patent for semaglutide, US Patent No. 9,249,190, is set to expire on March 2, 2027 [1]. However, it is important to note that this date is subject to change, as there may be additional patents or patent extensions that could prolong the exclusivity period for Novo Nordisk.

In summary, based on the information available from DrugPatentWatch.com, the expected semaglutide patent expiry date is March 2, 2027 [1]. However, it is advisable to monitor the patent landscape for any updates or changes that may impact the expiry date.

Sources:
[1] DrugPatentWatch.com. (n.d.). Semaglutide (US9249190). Retrieved from <https://www.drugpatentwatch.com/patent/US9249190>